Galera Therapeutics, Inc. (GRTXD)
OTC Markets OTCQB
Price as at 1 Oct 2026, 10:58 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Galera Therapeutics, Inc. trades at $18.99. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Galera Therapeutics, Inc.
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC). The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its GRTXD data?
Fundamentals for GRTXD come from company filings and exchange data, as listed on OTC Markets OTCQB; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 10:58 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for GRTXD, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.